KRSNAA

Krsnaa Diagnostics share price & financials

Price
₹540
Market cap
₹1.8k Cr
Sector
Healthcare
Calls analysed
7
Latest concall · Q1 FY27 · call held 14 Aug 2026

Krsnaa Diagnostics Limited Q1 FY27

Revenue from Operations 2,355 million +22%EBITDA 588 million EBITDA Margin 25% −2%PAT 166 million

What went well

  • Revenue from operations for Q1 FY27 stood at INR 2,355 million, representing a 22% year-on-year growth.
  • Retail revenue for Q1 FY27 grew at an impressive 64% year-on-year to INR 193 million, contributing approximately 9% of overall group revenue.
  • Krsnaa was awarded the Himachal Pradesh CT project for 34 CT scans, expanding its footprint in the state from 12 to 34 centers, with this project predominantly being cash-paying.

What to watch

  • EBITDA margin for Q1 FY27 compressed to 25% from 27% in Q1 FY26, primarily due to upfront costs, including onboarding 4,000 manpower in Rajasthan ahead of full revenue realization.
  • PAT for Q1 FY27 stood at INR 166 million, translating to a margin of 7%.
Read the full call →

What Krsnaa Diagnostics Limited does

Krsnaa Diagnostics operates a hub-and-spoke network of radiology (CT/MRI/X-ray), pathology and tele-radiology services across India, largely through Public-Private Partnership (PPP) contracts with government hospitals and health centres alongside a retail diagnostics arm. It earns by running these centres under long-tenure PPP contracts (radiology tenures average around 10+ years, pathology around 5+ years) and through a growing retail patient business (RPL) offering wellness packages, home collection and preventive health screening. The company also runs one of India's largest NABH-accredited tele-radiology reporting hubs, remotely reporting X-ray, CT and MRI scans for patients in remote locations.

Segments

  • Radiology
  • Pathology
  • Tele-radiology
  • Retail Diagnostics (RPL)
CT/MRI centres
190 (target 200+)
Pathology labs
147 (target 290+)
Patient collection centres
4,700+ (target 5,000+)
States/UTs presence
18
Districts presence (PAN India)
331
Patients served in last 5 years
68 million+
Company website

Guidance record · Q1 FY27

what the last two calls moved 16 tracked 1 delivered 5 missed 10 open
  • Retail Revenue Share delivered said Q4 FY25 Promised: 5% to 8% in FY26 Q1 FY27: Promise deadline has passed.
  • FY25 Revenue Growth missed said Q3 FY25 Promised: 25% YoY growth for FY25 Q1 FY27: Promise deadline has passed.
  • Retail Segment Profitability went quiet said Q1 FY26 Promised: Breakeven by the end of FY26 Q1 FY27: New target for Retail Pathology Labs (RPL) to be EBITDA positive by Q2 FY27. Q1 was EBITDA negative due to manpower deployment.

All 16 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 19.9%, net profit down 20.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue179 165 175 176 183 +2%159 −4%173 −1%211 +20%
EBITDA52 48 53 50 58 +12%48 +0%57 +8%57 +14%
Net profit22 22 21 20 23 +5%16 −27%43 +105%16 −20%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −34.9% 1Y

₹500₹600₹700₹800Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 10 Nov 2025Q3 FY26 — 6 Feb 2026Q4 FY26 — 26 May 2026Q1 FY27 — 14 Aug 2026

1Y: ₹845.45 on 10 Sept 2025 → ₹550.05. High ₹866.2 (23 Sept 2025), low ₹520.3 (30 Mar 2026).

How the price took the results

close before → close after

Q1 FY27
+3.3%
14 Aug
Q4 FY26
−0.9%
26 May
Q3 FY26
−2.8%
6 Feb
Q2 FY26
+7.6%
10 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 14.1% a year over 3 years, FY23 to FY26. Operating margin widened to 30.8%.

Year endingFY23FY24FY25FY26
Revenue₹465 Cr₹590 Cr₹682 Cr₹691 Cr
Operating profit₹124 Cr₹144 Cr₹196 Cr₹213 Cr
Operating margin26.7%24.4%28.7%30.8%
Interest₹7 Cr₹16 Cr₹24 Cr₹34 Cr
Depreciation₹54 Cr₹73 Cr₹88 Cr₹90 Cr
Net profit₹64 Cr₹58 Cr₹83 Cr₹102 Cr
Net margin13.8%9.8%12.2%14.8%
Cash from operations₹75 Cr₹24 Cr₹89 Cr₹134 Cr
Free cash flow₹-59 Cr₹-169 Cr₹-21 Cr₹-80 Cr
ROCE12.0%10.0%13.0%13.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹6 Cr₹16 Cr₹16 Cr₹16 Cr₹16 Cr₹16 Cr
Reserves₹-17 Cr₹671 Cr₹727 Cr₹799 Cr₹916 Cr₹976 Cr
Borrowings₹474 Cr₹41 Cr₹32 Cr₹160 Cr₹284 Cr₹531 Cr
Other liabilities₹146 Cr₹149 Cr₹134 Cr₹197 Cr₹287 Cr₹295 Cr
Total liabilities₹609 Cr₹877 Cr₹909 Cr₹1.2k Cr₹1.5k Cr₹1.8k Cr
Fixed assets₹309 Cr₹386 Cr₹471 Cr₹647 Cr₹680 Cr₹651 Cr
Capital work in progress₹4 Cr₹28 Cr₹25 Cr₹10 Cr₹30 Cr₹208 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹32 Cr₹58 Cr
Other assets₹297 Cr₹463 Cr₹413 Cr₹514 Cr₹761 Cr₹902 Cr
Total assets₹609 Cr₹877 Cr₹909 Cr₹1.2k Cr₹1.5k Cr₹1.8k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public trimmed −1.17 pp while FIIs added +0.88 pp. The shareholder count shrank 1% to 53,625.

Promoters
27.1%
FIIs
4.3%
DIIs
14.5%
Public
54.1%

Since Jun 2025

  • Public −1.17 pp
  • FIIs +0.88 pp
  • DIIs +0.27 pp

How it drifted, 12 quarters

Over this window the public went from 49.8% to 54.1% — +4.3 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 27.8%, FIIs 3.7%, DIIs 18.7%, Public 49.8%.Dec '23: Promoters 27.0%, FIIs 3.4%, DIIs 16.6%, Public 52.9%.Mar '24: Promoters 27.0%, FIIs 3.3%, DIIs 15.4%, Public 54.3%.Jun '24: Promoters 27.2%, FIIs 3.3%, DIIs 15.3%, Public 54.2%.Sep '24: Promoters 27.2%, FIIs 3.6%, DIIs 15.9%, Public 53.3%.Dec '24: Promoters 27.2%, FIIs 4.0%, DIIs 14.5%, Public 54.3%.Mar '25: Promoters 27.2%, FIIs 3.5%, DIIs 14.3%, Public 54.9%.Jun '25: Promoters 27.1%, FIIs 3.4%, DIIs 14.2%, Public 55.3%.Sep '25: Promoters 27.1%, FIIs 3.7%, DIIs 15.0%, Public 54.3%.Dec '25: Promoters 27.1%, FIIs 4.2%, DIIs 13.8%, Public 54.9%.Mar '26: Promoters 27.1%, FIIs 3.9%, DIIs 13.9%, Public 55.1%.Jun '26: Promoters 27.1%, FIIs 4.3%, DIIs 14.5%, Public 54.1%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Krsnaa Diagnostics Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Rajendra Khivraj Mutha 24.75%unchanged
Phi Capital Trust - Phi Capital Growth Fund - I 15.37%unchanged
Tata Mutual Fund- Tata Small Cap Fund Mutual fund8.04%unchanged
Krsna Diagnostics (Mumbai) Private Limited 2.36%unchanged
Amicorp Capital (Mauritius) Limited FPI fund2.18%unchanged
HDFC Life Insurance Company Limited Insurer2.05%unchanged
Bandhan Small Cap Fund Mutual fund1.98%newly disclosed
Medimaze Solutions Private Limited 1.03%unchanged
Bandhan BSE Healthcare Index Fund —off the list

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Expensive

To justify its price of ₹550, this stock must grow earnings at 19% every year for 7 years. Our analysis caps realistic growth at ~5%. At that growth it is worth ₹261 — downside of 53%.

Growth the price implies
18.8% a year
for 7 years, fading to 4%
It has actually compounded at
5.4% a year
net profit, FY23–FY26 · EPS 4.8%
The gap
0.1 pp
-53% downside if it only repeats history
Price today ₹550.05 Value at the reference growth ₹260.84

Change the assumptions yourself →

All earnings calls (7)

Read the Q1 FY27 call →

Learn to analyse Krsnaa Diagnostics Limited

Guides on how to read this kind of business and the numbers that matter.